Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17793832 | 0.85 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL30465921 | 0.84 | HCRTR1 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL13208901 | 0.84 | POLB (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL30443501 | 0.82 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL1671087 | 0.82 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL27056184 | 0.82 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL19741948 | 0.81 | HCRTR1 (0.65) | HCRTR1HCRTR2 | |
| SCHEMBL19549868 | 0.81 | HCRTR1 (0.66) | HCRTR1HCRTR2 | |
| SCHEMBL17859340 | 0.81 | HCRTR1 (0.66) | HCRTR1HCRTR2 | |
| SCHEMBL19549869 | 0.81 | HCRTR1 (0.66) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3380475-A1 | OCTAHYDROPYRROLO [3, 4-c | Sunshine Lake Pharma Co., Ltd. (CN) | 2018-10-03 | — | — | EP | disclosed |
| US-9987255-B2 | 5,5-bicyclic oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987255-B2 | 5,5-bicyclic oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170368035-A1 | 5,5-Bicyclic Oxazole Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2017-12-28 | — | — | US | disclosed |
| WO-2017088759-A1 | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-06-01 | — | — | WO | disclosed |
| WO-2016100162-A2 | 5,5-BICYCLIC OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368035-A1 | 5,5-Bicyclic Oxazole Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY5R | HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.